Walaa A Alshahrani
Overview
Explore the profile of Walaa A Alshahrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
1
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almutairi A, Alshahrani W, Alhathlol G, Alsheikh F, Alakeel A, Al Yami M, et al.
Saudi Pharm J
. 2024 Dec;
32(12):102203.
PMID: 39697471
Introduction: Evolocumab's short-term efficacy and safety were proven in phase-3 clinical trial, but its long-term safety and effectiveness in the Saudi population are yet to be studied. The aim of...
2.
Almohareb S, Alfayez O, Aljuaid S, Alshahrani W, Bakhsh G, Alshammari M, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518671
: GLP-1 receptor agonists (GLP-1RA) are used in the management of type II diabetes mellitus or obesity, although its role in patients with type I diabetes mellitus (T1DM) has been...
3.
Alshahrani W, Alshahrani R, Alkathiri M, Alay S, Alabkka A, Alaraj S, et al.
Am J Cardiovasc Drugs
. 2024 Sep;
24(6):823-839.
PMID: 39254826
Background: Direct oral anticoagulants (DOACs) have shown comparable efficacy and a superior safety profile in clinical trials for patients with venous thromboembolism (VTE). However, further study is needed to assess...
4.
Alsowaida Y, Al Sulaiman K, Mahrous A, Alharbi A, Bifari N, Alshahrani W, et al.
Int J Infect Dis
. 2024 Sep;
148:107234.
PMID: 39241957
Objectives: To evaluate the clinical outcomes of anidulafungin for candidemia treatment in critically ill patients with obesity. Methods: A multicenter, retrospective cohort study was conducted in Saudi Arabia for critically...
5.
Al Sulaiman K, Aljuhani O, Alkofide H, Aljohani M, Badreldin H, Al Harbi M, et al.
Thromb J
. 2024 May;
22(1):43.
PMID: 38778323
Background: Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently investigating the use of Apixaban in underweight patients,...
6.
Alsulami M, Al-Otaibi N, Alshahrani W, Altheaby A, Al Thiab K, Alnajjar L, et al.
Am J Nephrol
. 2024 Apr;
55(4):487-498.
PMID: 38679014
Introduction: Kidney transplantation is a definitive treatment for end-stage renal disease. It is associated with improved life expectancy and quality of life. One of the most common complications following kidney...